BeyondSpring Inc. — FY2019 Form 20-F
Reporting period: Fiscal year ended December 31, 2019. This is an annual report, not a standalone fourth-quarter filing; the text does not provide separate Q4 financial results. Financial statements are audited and prepared under U.S. GAAP.
Business context
BeyondSpring is a clinical-stage biopharmaceutical company with no approved products and no product-sale revenue. Its lead candidate, Plinabulin, is in late-stage trials for chemotherapy-induced neutropenia (CIN) and advanced non-small cell lung cancer (NSCLC). It also has early-stage immuno-oncology programs. BeyondSpring owns global Plinabulin rights except in China, where its subsidiary Wanchun Bulin holds the rights and BeyondSpring owns a 57.97% interest.
Key financial metrics
| Metric | FY2019 / Dec. 31, 2019 | FY2018 / Dec. 31, 2018 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $31.3 million | $51.6 million |
| General and administrative expense | $9.0 million | $5.9 million |
| Operating loss | $40.3 million | $57.5 million |
| Net loss | $40.3 million | $57.5 million |
| Net loss attributable to BeyondSpring | $38.1 million | $54.9 million |
| Basic and diluted loss per share | $1.55 | $2.42 |
| Net cash used in operating activities | $48.2 million | $40.0 million |
| Cash and cash equivalents | $35.9 million | $3.9 million |
| Total assets | $44.6 million | $7.1 million |
| Total liabilities | $13.4 million | $16.4 million |
| Total equity (deficit) | $31.1 million | $(9.4) million |
Margins are not meaningful because the company reported no revenue. At year-end, current assets were $40.9 million and current liabilities were $10.1 million, yielding net current assets of $30.8 million. The balance sheet reported $1.4 million of long-term loans; contractual debt obligations were $1.6 million. Operating lease liabilities were $2.5 million, with $3.0 million of undiscounted lease payments.
Material changes versus the prior comparable period
- Net loss narrowed by 30%, primarily as R&D expense fell 39% ($20.3 million). Management attributed the R&D decline mainly to lower clinical-trial spending, share-based compensation, and consultant and other costs.
- G&A expense rose 51% to $9.0 million, driven primarily by higher share-based compensation, professional fees, salaries, and benefits.
- Despite lower reported R&D expense and net loss, operating cash use increased by $8.2 million, to $48.2 million, largely reflecting increased cash spending on Plinabulin development.
- Cash increased by $32.0 million. Financing activities provided $80.2 million, including $69.5 million of net proceeds from ordinary-share issuance, $10.1 million from noncontrolling interests, and loan proceeds net of repayments. Ordinary shares outstanding increased from 23.2 million to 27.9 million.
- Total equity improved from a $9.4 million deficit to $31.1 million, primarily reflecting equity financing and subsidiary investment.
Outlook, risks, contingencies, and unusual items
- Liquidity and runway: Management said cost reductions—including deferral of certain research, development, and clinical projects and lower administrative spending—were expected to allow existing resources to cover operating expenses and capital expenditures into the second quarter of 2021. This estimate depends on implementing those measures and is not a guarantee. The company expects to need additional financing; failure to obtain it could force further delays or cuts.
- Clinical and regulatory milestones: Study 103, a 554-patient Phase 3 NSCLC trial, had enrolled more than 500 patients. The second interim analysis was being evaluated; final results were expected in the second half of 2020 if the study continued. Management planned Chinese NDA submissions for NSCLC and CIN in 2020, and U.S. submissions after final trial results, subject to positive outcomes. The CIN NDA rolling submission in China had begun in Q1 2020. These were expectations, not approvals.
- Trial uncertainty: Study 101 did not meet its primary overall-survival endpoint in the full intent-to-treat population; the favorable NSCLC findings cited by the company came from a small, post hoc subgroup and were not statistically significant for overall survival. Later-stage trials may fail, require additional subjects or studies, or yield different results.
- COVID-19: The filing reports severe effects on trial enrollment in Ukraine and possible disruption to other enrollment, CRO activity, clinical supplies, regulatory timelines, and financing. The overall duration and financial effect were not estimable.
- Other key risks: The company has no commercial products or sales infrastructure and depends on third parties for trials and manufacturing. It identifies BASF as the sole supplier of the formulation stabilizer Solutol, creating reformulation and delay risk if supply is interrupted. Additional risks include dilution from future equity financing, competition, safety and regulatory hurdles, China-related regulation and cash-transfer restrictions, and currency exposure.
- Unusual items: 2017 R&D expense included a $42.3 million noncash charge for shares issued to terminate Plinabulin royalty arrangements. FY2019 share-based compensation was $2.1 million. The company adopted lease accounting guidance in 2019, recording $2.5 million of year-end right-of-use assets and $2.5 million of lease liabilities.
- Controls and contingencies: Management reported effective disclosure controls and internal control over financial reporting at December 31, 2019; the auditor did not attest to internal-control effectiveness. The filing states that no material legal proceedings were pending.
Most important facts for investors to verify
- Whether Study 103 and the CIN Phase 3 studies met their primary endpoints, and whether final results support the planned NDA submissions.
- Whether cash burn, cost reductions, and financing availability support the stated runway into Q2 2021; review subsequent financing and share-count changes.
- Whether Chinese conditional or priority review pathways are available to Plinabulin and what post-approval obligations they would entail.
- How COVID-related trial, regulatory, and manufacturing disruptions affected actual timelines and costs after the filing date.
- The terms and economic impact of the China subsidiary’s minority ownership, investor rights, and restrictions on moving cash to the parent.